Cladribine considerations in the era of COVID-19

Sponsored by Merck Australia

A recent analysis suggests that the immune repopulation pattern in people treated with cladribine (Mavenclad) may contribute to the ability to mount an immune response to infection and develop protective antibodies upon vaccination.1 The limbic spoke with Professor David Baker, Professor of Neuroimmunology at London’s Queen Mary University, about the relevance of cladribine’s mechanism of ...

Already a member?

Login to keep reading.

© 2021 the limbic